NCT00475072View on ClinicalTrials.gov

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions

Hepatitis C, Chronic

Interventions

DRUG

peginterferon alfa-2a [Pegasys]

180 micrograms sc weekly for 48 weeks

DRUG

ribavirin

1000/1200mg po daily for 48 weeks

Trial Locations (1)

02990

Mexico City

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00475072 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C. | Biotech Hunter | Biotech Hunter